ABSTRACT
As the world fights the COVID-19 pandemic, point-of-care detection and diagnostic systems have gained immense importance. Microfluidics has revolutionized the domain of point-of-care (PoC) devices meant for the on-site detection of diseases. Microfluidic platforms provide an integrated, miniaturized, and cost-effective analytical alternative to conventional point-of-care devices with a massive potential for commercialization. These platforms also offer the additional advantage of low sample volume and lesser time for detection. The amalgamation of nanobiotechnology with microfluidics has given rise to highly selective and sensitive stand-alone devices that detect early disease onset and progression biomarkers. Early detection helps to decide the therapeutic strategy for the patient in as little time as possible. These devices are compact, portable, and convenient, hence ideal for PoC applications. The incorporation of nanoscale sensing elements, including nanoprobes, graphene, and magnetic and noble metal nanoparticles (Gold, Silver, and Platinum), further enhances the sensitivity of nanobiosensor-based immunoassays. The future of medical diagnostics heavily relies on these novel sensing platforms, thus helping in proper planning and management of the treatment of any disease. In this chapter, to better understand, we illustrate the fabrication, characterization, and applications of these intelligent point-of-care biosensing platforms. A brief account of challenges and future scope associated with applying such point-of-care nanobiosensors has also been discussed. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2022.